Drugs and Drug Candidates最新文献_第2页

Revolutionizing Drug Discovery: A Comprehensive Review of AI Applications 革新药物发现：人工智能应用综述

Drugs and Drug Candidates Pub Date : 2024-02-13 DOI: 10.3390/ddc3010009

Rushikesh Dhudum, Ankit Ganeshpurkar, Atmaram Pawar

{"title":"Revolutionizing Drug Discovery: A Comprehensive Review of AI Applications","authors":"Rushikesh Dhudum, Ankit Ganeshpurkar, Atmaram Pawar","doi":"10.3390/ddc3010009","DOIUrl":"https://doi.org/10.3390/ddc3010009","url":null,"abstract":"The drug discovery and development process is very lengthy, highly expensive, and extremely complex in nature. Considering the time and cost constraints associated with conventional drug discovery, new methods must be found to enhance the declining efficiency of traditional approaches. Artificial intelligence (AI) has emerged as a powerful tool that harnesses anthropomorphic knowledge and provides expedited solutions to complex challenges. Advancements in AI and machine learning (ML) techniques have revolutionized their applications to drug discovery and development. This review illuminates the profound influence of AI on diverse aspects of drug discovery, encompassing drug-target identification, molecular properties, compound analysis, drug development, quality assurance, and drug toxicity assessment. ML algorithms play an important role in testing systems and can predict important aspects such as the pharmacokinetics and toxicity of drug candidates. This review not only strengthens the theoretical foundation and development of this technology, but also explores the myriad challenges and promising prospects of AI in drug discovery and development. The combination of AI and drug discovery offers a promising strategy to overcome the challenges and complexities of the pharmaceutical industry.","PeriodicalId":131152,"journal":{"name":"Drugs and Drug Candidates","volume":"43 23","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139839695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beta-Thalassemia: A Pharmacological Drug-Based Treatment β-地中海贫血症：基于药物的治疗

Drugs and Drug Candidates Pub Date : 2024-02-08 DOI: 10.3390/ddc3010008

Shrabonti Biswas, S. Smrity, Md. Shimul Bhuia, Fatema Akter Sonia, Mst. Asma Aktar, R. Chowdhury, Tawhida Islam, Muhammad Torequl Islam, Gabriel Gonçalves Alencar, C. Paulo, Ana Pavla Almeida Diniz Gurgel, H. Coutinho

{"title":"Beta-Thalassemia: A Pharmacological Drug-Based Treatment","authors":"Shrabonti Biswas, S. Smrity, Md. Shimul Bhuia, Fatema Akter Sonia, Mst. Asma Aktar, R. Chowdhury, Tawhida Islam, Muhammad Torequl Islam, Gabriel Gonçalves Alencar, C. Paulo, Ana Pavla Almeida Diniz Gurgel, H. Coutinho","doi":"10.3390/ddc3010008","DOIUrl":"https://doi.org/10.3390/ddc3010008","url":null,"abstract":"This review was performed to determine the potential of drugs that can remove or decrease the requirements for blood transfusion among beta (β)-thalassemia patients. A comprehensive literature search was conducted to identify clinical trials and studies using PubMed Central, Google Scholar, PubMed, and ScienceDirect archived articles published from 1996 to November 2023. According to this review, clinical trials for a number of drugs, including luspatercept, sotatercept, mitapivat, etavopivat, hydroxyurea, rapamycin, decitabine, thalidomide, and quercetin, have been performed as part of efforts to improve the cure strategy for β-thalassemia. Of these drugs, luspatercept and sotatercept have exhibited particularly promising results and have been granted US Food and Drug Administration (FDA) approval for use in β-thalassemia patients. The mode of action for the drugs luspatercept and sotatercept involves the stimulation of hemoglobin (Hb) production or enhancement of its functionality, thereby decreasing reliance on blood transfusions and enhancing the overall quality of life. In this way, drugs like luspatercept and sotatercept present an opportunity to notably decrease the necessity for blood transfusions in β-thalassemia patients, improving their standard of living and overall prognosis. However, more research is needed to evaluate the effectiveness and safety of these drugs in the long run.","PeriodicalId":131152,"journal":{"name":"Drugs and Drug Candidates","volume":"82 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139851687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beta-Thalassemia: A Pharmacological Drug-Based Treatment β-地中海贫血症：基于药物的治疗

Drugs and Drug Candidates Pub Date : 2024-02-08 DOI: 10.3390/ddc3010008

Shrabonti Biswas, S. Smrity, Md. Shimul Bhuia, Fatema Akter Sonia, Mst. Asma Aktar, R. Chowdhury, Tawhida Islam, Muhammad Torequl Islam, Gabriel Gonçalves Alencar, C. Paulo, Ana Pavla Almeida Diniz Gurgel, H. Coutinho

{"title":"Beta-Thalassemia: A Pharmacological Drug-Based Treatment","authors":"Shrabonti Biswas, S. Smrity, Md. Shimul Bhuia, Fatema Akter Sonia, Mst. Asma Aktar, R. Chowdhury, Tawhida Islam, Muhammad Torequl Islam, Gabriel Gonçalves Alencar, C. Paulo, Ana Pavla Almeida Diniz Gurgel, H. Coutinho","doi":"10.3390/ddc3010008","DOIUrl":"https://doi.org/10.3390/ddc3010008","url":null,"abstract":"This review was performed to determine the potential of drugs that can remove or decrease the requirements for blood transfusion among beta (β)-thalassemia patients. A comprehensive literature search was conducted to identify clinical trials and studies using PubMed Central, Google Scholar, PubMed, and ScienceDirect archived articles published from 1996 to November 2023. According to this review, clinical trials for a number of drugs, including luspatercept, sotatercept, mitapivat, etavopivat, hydroxyurea, rapamycin, decitabine, thalidomide, and quercetin, have been performed as part of efforts to improve the cure strategy for β-thalassemia. Of these drugs, luspatercept and sotatercept have exhibited particularly promising results and have been granted US Food and Drug Administration (FDA) approval for use in β-thalassemia patients. The mode of action for the drugs luspatercept and sotatercept involves the stimulation of hemoglobin (Hb) production or enhancement of its functionality, thereby decreasing reliance on blood transfusions and enhancing the overall quality of life. In this way, drugs like luspatercept and sotatercept present an opportunity to notably decrease the necessity for blood transfusions in β-thalassemia patients, improving their standard of living and overall prognosis. However, more research is needed to evaluate the effectiveness and safety of these drugs in the long run.","PeriodicalId":131152,"journal":{"name":"Drugs and Drug Candidates","volume":" 44","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139791951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nose-to Brain Delivery of Resveratrol, a Non-Invasive Method for the Treatment of Cerebral Ischemia 从鼻子到大脑输送白藜芦醇，一种治疗脑缺血的非侵入性方法

Drugs and Drug Candidates Pub Date : 2024-01-26 DOI: 10.3390/ddc3010007

I. Alquisiras-Burgos, Irma Gabriela González-Herrera, Sergio Alcalá-Alcalá, P. Aguilera

{"title":"Nose-to Brain Delivery of Resveratrol, a Non-Invasive Method for the Treatment of Cerebral Ischemia","authors":"I. Alquisiras-Burgos, Irma Gabriela González-Herrera, Sergio Alcalá-Alcalá, P. Aguilera","doi":"10.3390/ddc3010007","DOIUrl":"https://doi.org/10.3390/ddc3010007","url":null,"abstract":"Cerebral ischemia represents a particular condition among neurological diseases due to its high frequency, high associated mortality, and the permanent disability in patients that survive it. Numerous studies in animal models have demonstrated the protective properties of resveratrol against cerebral ischemia. Resveratrol is a soluble molecule in polar solvents with high membrane permeability; however, it is rapidly metabolized at the liver and is also a substrate of the ATP binding cassette transporters located at the blood–brain barrier. These circumstances reduced bioavailability of resveratrol to the brain. In this review, we examined nasal resveratrol’s formulations including nanocarriers such as nanostructured lipid carriers, nanoemulsions, nanoparticles, bilosomes, cubosomal, and transferosomes that are directly transported to the brain. An intranasal administration route evades resveratrol transformation due to liver metabolism. Components of nanoformulations increased resveratrol absorption to the brain by enhancing permeation through specific approaches and also maintaining stability during storage. Both characteristics improved the delivery of resveratrol with conserved antioxidant capacity and protective properties for neurological models. Although demonstration that the nanoformulations prevents resveratrol’s blood–brain barrier retention is missing, properties of resveratrol’s nanoformulation encourage testing in clinical trials; however, regulatory approval for a novel nanocarrier in nasal drug delivery is complicated and needs approval.","PeriodicalId":131152,"journal":{"name":"Drugs and Drug Candidates","volume":"80 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140494619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Opportunities and Difficulties in the Repurposing of HDAC Inhibitors as Antiparasitic Agents 将 HDAC 抑制剂重新用作抗寄生虫药物的机遇与困难

Drugs and Drug Candidates Pub Date : 2024-01-18 DOI: 10.3390/ddc3010006

Tapas K Mohapatra, Reena Rani Nayak, Ankit Ganeshpurkar, Prashant Tiwari, Dileep Kumar

{"title":"Opportunities and Difficulties in the Repurposing of HDAC Inhibitors as Antiparasitic Agents","authors":"Tapas K Mohapatra, Reena Rani Nayak, Ankit Ganeshpurkar, Prashant Tiwari, Dileep Kumar","doi":"10.3390/ddc3010006","DOIUrl":"https://doi.org/10.3390/ddc3010006","url":null,"abstract":"Ongoing therapy for human parasite infections has a few known drugs but with serious side effects and the problem of drug resistance, impelling us to discover novel drug candidates with newer mechanisms of action. Universally, this has boosted the research in the design and development of novel medicinal agents as antiparasitic drugs with a novel mode of action. Histone deacetylase inhibitors (HDACis) are used in a vast variety of diseases due to their anti-inflammatory properties. Drug repurposing strategies have already approved HDACis as cancer therapeutics and are now under investigation for many parasitic infections. Along with the expression of the gene, histone deacetylase (HDAC) enzymes also act as a slice of great multi-subunit complexes, targeting many non-histones, changing systemic and cellular levels signaling, and producing different cell-based specified effects. Zinc (Zn2+)- and nicotinamide adenine dinucleotide (NAD+)-dependent HDACs of parasites play pivotal roles in the alteration of gene expression of parasites. Some of them are already known to be responsible for the survival of several parasites under odd circumstances; thus, targeting them for therapeutic interventions will be novel for potential antiparasitic targets. This point of view outlines the knowledge of both class-I and class-II HDACis and sirtuin inhibitors that emerged to be the key players in the treatment of human parasitic disorders like Leishmaniasis, Schistosomiasis, Malaria, Trypanosomiasis, and Toxoplasmosis. This review also focuses on repurposing opportunities and challenges in HDAC inhibitors that are preceded by their clinical development as potent new antiparasitic drugs.","PeriodicalId":131152,"journal":{"name":"Drugs and Drug Candidates","volume":"80 18","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139526341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Effects of Vitamin D on Preventing Hyperglycemia and a Novel Approach to Its Treatment 维生素 D 对预防高血糖的作用及治疗高血糖的新方法

Drugs and Drug Candidates Pub Date : 2023-11-28 DOI: 10.3390/ddc2040046

Suchitra Monapati, Pavani Kaki, Mary Stella Gurajapu, Prathibha Guttal Subhas, Harinadha Baba Kudipudi

{"title":"The Effects of Vitamin D on Preventing Hyperglycemia and a Novel Approach to Its Treatment","authors":"Suchitra Monapati, Pavani Kaki, Mary Stella Gurajapu, Prathibha Guttal Subhas, Harinadha Baba Kudipudi","doi":"10.3390/ddc2040046","DOIUrl":"https://doi.org/10.3390/ddc2040046","url":null,"abstract":"The dietary reference levels for vitamin D were established with an emphasis on its role in bone health; however, with the identification of vitamin D receptors in all body tissues novel associations with other metabolic disorders, such as diabetes, are being researched. Aside from its standard function as the main regulator of calcium absorption, vitamin D also controls the calcium pool, mediates the activity of beta cell calcium-dependent endopeptidases, encourages the conversion of proinsulin to insulin, increases insulin output, and raises insulin activity in peripheral insulin target tissues. Both immune cells and pancreatic beta cells include vitamin D receptors. A deficiency of vitamin D causes glucose intolerance and affects insulin secretion. Different pathogenic characteristics of the disease are linked to a number of vitamin D-related genes. It has been proven that vitamin D supplementation lowers the risk of type 1 and type 2 diabetes and its associated problems. In this article, we discussed a few prospective clinical trials on vitamin D that are necessary to clearly demonstrate the role of vitamin D in the prevention and management of diabetes.","PeriodicalId":131152,"journal":{"name":"Drugs and Drug Candidates","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139223990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanoscale Self-Assemblies from Amphiphilic Block Copolymers as Proficient Templates in Drug Delivery 两亲嵌段共聚物的纳米级自组装作为药物输送的有效模板

Drugs and Drug Candidates Pub Date : 2023-11-22 DOI: 10.3390/ddc2040045

Dhruvi Patel, K. Kuperkar, S. Yusa, P. Bahadur

{"title":"Nanoscale Self-Assemblies from Amphiphilic Block Copolymers as Proficient Templates in Drug Delivery","authors":"Dhruvi Patel, K. Kuperkar, S. Yusa, P. Bahadur","doi":"10.3390/ddc2040045","DOIUrl":"https://doi.org/10.3390/ddc2040045","url":null,"abstract":"This review article emphasizes the current enlargements in the formation and properties of the various nanostructured aggregates resulting from the self-assembly of a variety of block copolymers (BCPs) in an aqueous solution. The development of the different polymerization techniques which produce polymers with a desired predetermined molecular weight and low polydispersity is investigated with regard to their technological and biomedical applications; in particular, their applications as vehicles for drug delivery systems are considered. The solution behavior of amphiphilic BCPs and double-hydrophilic block copolymers (DHBCs), with one or both blocks being responsive to any stimulus, is discussed. Polyion complex micelles (PICMs)/polymersomes obtained from the electrostatic interaction of a polyelectrolyte-neutral BCP with oppositely charged species are also detailed. Lastly, polymerization-induced self-assembly (PISA), which forms nanoscale micellar aggregates with controlled size/shape/surface functionality, and the crystallization-driven self-assembly of semicrystalline BCPs facilitated when one block of the BCP is crystallizable, are also revealed. The scalability of the copolymeric micelles in the drug delivery systems and pharmaceutical formations that are currently being used in clinical trials, research, or preclinical testing is emphasized as these micelles could be used in the future to create novel nanomedicines. The updated literature and the future perspectives of BCP self-assembly are considered.","PeriodicalId":131152,"journal":{"name":"Drugs and Drug Candidates","volume":"287 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139250030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Kappa Opioid Receptor: Candidate Pharmacotherapeutic Target for Multiple Sclerosis 阿片受体:多发性硬化症的候选药物治疗靶点

Drugs and Drug Candidates Pub Date : 2023-11-10 DOI: 10.3390/ddc2040044

Brian Reed, Surya Dutta

引用次数: 0

Repositioning Oxybutynin Hydrochloride: State of the Art in Synthesis, Mode of Action, Metabolism, and Formulations 盐酸奥昔布宁的重新定位:合成、作用方式、代谢和配方的最新进展

Drugs and Drug Candidates Pub Date : 2023-10-24 DOI: 10.3390/ddc2040043

Jean Jacques Vanden Eynde

引用次数: 0

Ethnomedicinal Uses, Phytochemistry, and Pharmacological Activity of the Irvingia Species 鸢尾属植物的民族医药用途、植物化学和药理活性

Drugs and Drug Candidates Pub Date : 2023-10-17 DOI: 10.3390/ddc2040042

Branly-Natalien Nguena-Dongue, Boniface Pone Kamdem, Paul Keilah Lunga, Fabrice Fekam Boyom

{"title":"Ethnomedicinal Uses, Phytochemistry, and Pharmacological Activity of the Irvingia Species","authors":"Branly-Natalien Nguena-Dongue, Boniface Pone Kamdem, Paul Keilah Lunga, Fabrice Fekam Boyom","doi":"10.3390/ddc2040042","DOIUrl":"https://doi.org/10.3390/ddc2040042","url":null,"abstract":"Plants belonging to the genus Irvingia are widespread across the African and Southeast Asian regions of the world. Irvingia gabonensis, Irvingia malayana, and Irvingia grandifolia are among the commonly used species in ethnomedicine, especially in Africa. Fever, scabies, toothache, inflammation, and liver and gastrointestinal disorders are among the pathological conditions that are reverted by Irvingia plants upon traditional preparations. Modern pharmacological investigations have substantiated the ethnomedicinal uses of Irvingia spp. Reports on the phytochemical analysis of Irvingia plants have revealed the presence of a number of secondary metabolites such as flavonoids, phenolic compounds, tannins, saponins, and alkaloids. Based on the foregoing, the present study provides a comprehensive evaluation of reports on the ethnomedicinal use, phytochemistry, pharmacology, and toxicity of plants from the genus Irvingia. Relevant information on Irvingia plants was mostly obtained from major scientific databases from their inception until July 2023. As a result, more than forty compounds have been identified in Irvingia spp., proving the abundance of secondary metabolites in these plants. Reports have pointed out modern pharmacological activities such as antiprotozoal, antimicrobial, antioxidant, antidiabetic, anti-inflammatory, and hepatoprotective activities. The present study provides more insights for the successful utilization of Irvingia plants and may guide further research on their therapeutic potential in the treatment of various diseases.","PeriodicalId":131152,"journal":{"name":"Drugs and Drug Candidates","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135994013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0